Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Jonathan E RosenbergKarla A BallmanSusan HalabiPamela J AthertonAmir MortazaviChristopher J SweeneyWalter M StadlerBenjamin A TeplyJoel PicusScott T TagawaSreedhar KatragaddaDaniel VaenaJamal MislehChristopher J HoimesElizabeth R PlimackThomas W FlaigRobert DreicerDean F BajorinOlwen HahnEric J SmallMichael J MorrisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The addition of bevacizumab to GC did not result in improved OS. The observed median OS of about 14 months is consistent with prior phase III trials of cisplatin-based chemotherapy.